Cellectar Biosciences Inc - CLRB Enterprise Value-to-Sales Ratio

Official company branding of cellectar.com (CLRB)

The expected transition to commercialization within the orphan oncology niche will establish a foundation for high cash flow margins for Cellectar Biosciences (CLRB). The EV/Sales ratio confirms this trend, where 0.00 represents the current value of the metric. Experienced management is successfully preparing regulatory filings, while innovative radiopharmaceuticals ensure high-precision destruction of cancer cells through targeted radiation delivery to the tumor.

Cellectar Corp (CLRB): Company Value to Revenue from 11/23/2025 to 11/20/2026

Cellectar - analytical breakdowns and key metrics (CLRB)

Fundamental company valuation:CLRB, cellectar.com
Manufactured products of Cellectar Biosciences Inc

The specifics of delivering radiopharmaceuticals with short half-lives require colossal expenditures on ultra-fast logistics, which directly impacts the operational efficiency of Cellectar Biosciences (CLRB). The EV/Sales valuation reflects the enterprise value including net debt relative to revenue, allowing investors to assess the density of market expectations and the probability of price deviation from fundamental values during periods of low liquidity.